Mitomycin Accord (Mitomycin)

Mitomycin is reduced inside hypoxic tumour cells to generate reactive intermediates that form covalent cross‑links between DNA strands. These cross‑links block DNA replication and transcription, leading to apoptosis of rapidly dividing cancer cells.

The dose of Mitomycin Accord is individualized by the prescribing oncologist based on the specific cancer type, treatment protocol, patient weight, renal function and prior therapy. No fixed regimen is provided here.

Mitomycin is classified as potentially harmful to the fetus and is generally contraindicated during pregnancy unless the therapeutic benefit outweighs the risk. It is also excreted in breast milk, so breastfeeding is not recommended while receiving the drug.

To order Mitomycin Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mitomycin belongs to the antineoplastic antibiotic class, whereas agents like cisplatin are platinum‑based alkylating compounds. Both have DNA‑targeting mechanisms, but Mitomycin’s cross‑linking is activated under low‑oxygen conditions, offering a distinct cytotoxic profile that can be advantageous in hypoxic tumours.

Mitomycin Accord should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Use aseptic technique when preparing the solution for intravenous or intravesical administration.

Mitomycin Accord is supplied as a sterile solution for injection. It can be given intravenously as part of systemic chemotherapy regimens or instilled intravesically directly into the bladder for local treatment of non‑muscle‑invasive bladder cancer.

The most serious risks include bone marrow failure leading to severe pancytopenia, life‑threatening infections, pulmonary toxicity such as interstitial pneumonitis, renal impairment, hemolytic‑uremic syndrome and severe allergic reactions that may require immediate medical attention.

Patients with severe renal impairment, uncontrolled infections, known hypersensitivity to Mitomycin or related compounds, and those who are pregnant or breastfeeding without a clear therapeutic justification should not receive Mitomycin Accord. Clinical judgment is essential for each individual case.